Dogwood Therapeutics
Price & Volume
Stats
See more52W Range | $2.60-$14.69 |
Market Cap | $88.2M |
Shares Short | 63,632 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$25.59 |
News
See moreYahoo Finance • 2 months ago
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Yahoo Finance • 4 months ago
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Yahoo Finance • 5 months ago
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
Yahoo Finance • 6 months ago
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
About
CEO | Mr. Gregory Duncan |
CFO | Ms. Angela Walsh |
Address | 44 Milton Avenue, Alpharetta, GA, United States, 30009 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 12 |
